Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
CAMBRIDGE, Mass., April 26, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Deutsche Bank 42nd Annual Health Care Conference. The presentation is scheduled for Wednesday, May 3rd at 10:00 a.m. ET.
A webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
